Covered recipient · General Payments record
JUAN EDUARDO GUZMAN
Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry
General Payments · PY2018–2024
$2,500.40
- Reported across 158 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $494.69 | 33 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $317.12 | 25 |
| Otsuka America Pharmaceutical, Inc. | $57.64 | 2 |
| Alkermes, Inc. | $24.63 | 1 |
| Axsome Therapeutics, Inc. | $22.90 | 1 |
| E.R. Squibb & Sons, L.L.C. | $22.61 | 1 |
| Teva Pharmaceuticals USA, Inc. | $17.79 | 1 |
| Neurocrine BioSciences, Inc. | $16.30 | 1 |
| ITI, Inc. | $15.70 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (33)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $16.97 | 01/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103857193 | CMS |
| ABBVIE INC. | $5.04 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103857195 | CMS |
| ABBVIE INC. | $22.36 | 02/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103857197 | CMS |
| ABBVIE INC. | $28.76 | 03/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103857199 | CMS |
| ABBVIE INC. | $8.78 | 03/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103857201 | CMS |
| ABBVIE INC. | $26.51 | 03/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103857203 | CMS |
| ABBVIE INC. | $14.81 | 04/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103857205 | CMS |
| ABBVIE INC. | $5.84 | 04/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103857207 | CMS |
| ABBVIE INC. | $21.71 | 04/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103857209 | CMS |
| ABBVIE INC. | $2.08 | 05/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103857211 | CMS |
| ABBVIE INC. | $6.46 | 05/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103857213 | CMS |
| ABBVIE INC. | $14.83 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103857215 | CMS |
| ABBVIE INC. | $5.39 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103857217 | CMS |
| ABBVIE INC. | $5.98 | 06/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103857219 | CMS |
| ABBVIE INC. | $25.00 | 07/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103857221 | CMS |
| ABBVIE INC. | $15.55 | 07/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103857223 | CMS |
| ABBVIE INC. | $2.42 | 07/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103857225 | CMS |
| ABBVIE INC. | $15.74 | 08/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103857227 | CMS |
| ABBVIE INC. | $19.93 | 08/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103857229 | CMS |
| ABBVIE INC. | $13.08 | 09/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103857231 | CMS |
| ABBVIE INC. | $19.00 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103857233 | CMS |
| ABBVIE INC. | $4.31 | 09/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103857235 | CMS |
| ABBVIE INC. | $6.07 | 10/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103857237 | CMS |
| ABBVIE INC. | $5.79 | 11/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103857239 | CMS |
| ABBVIE INC. | $4.71 | 12/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103857241 | CMS |
| Alkermes, Inc. | $24.63 | 11/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120510089 | CMS |
| Axsome Therapeutics, Inc. | $22.90 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148286179 | CMS |
| E.R. Squibb & Sons, L.L.C. | $22.61 | 11/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101302165 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.70 | 02/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143237286 | CMS |
| Neurocrine Biosciences, Inc. | $16.30 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150871291 | CMS |
| Otsuka America Pharmaceutical, Inc. | $25.26 | 09/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118903256 | CMS |
| Otsuka America Pharmaceutical, Inc. | $32.38 | 11/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118903258 | CMS |
| Teva Pharmaceuticals USA, Inc. | $17.79 | 10/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151739350 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.